EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Malignant Pleural Mesothelioma - Pipeline Review, H1 2015

  • ID: 3293061
  • Report
  • May 2015
  • 199 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • Biogen, Inc.
  • CanBas Co., Ltd.
  • GlaxoSmithKline plc
  • MolMed S.p.A.
  • Pfizer Inc.
  • MORE
Malignant Pleural Mesothelioma - Pipeline Review, H1 2015

Summary

This, ‘Malignant Pleural Mesothelioma - Pipeline Review, H1 2015’, provides an overview of the Malignant Pleural Mesothelioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • Biogen, Inc.
  • CanBas Co., Ltd.
  • GlaxoSmithKline plc
  • MolMed S.p.A.
  • Pfizer Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Malignant Pleural Mesothelioma Overview
Therapeutics Development
Pipeline Products for Malignant Pleural Mesothelioma - Overview
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes
Malignant Pleural Mesothelioma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Malignant Pleural Mesothelioma - Products under Development by Companies
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Advantagene, Inc.
Amphera BV
Bayer AG
Biogen, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CanBas Co., Ltd.
Concordia Healthcare Corp.
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline plc
Juno Therapeutics Inc.
MedImmune, LLC
Merck & Co., Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Oxford BioMedica plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Verastem, Inc.
Virttu Biologics Limited
Malignant Pleural Mesothelioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amatuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anetumab ravtansine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ascrinvacumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BG-00001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-986148 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BNC-105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBP-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRS-207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
defactinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FP-1039 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLONC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2256098 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV-1716 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iCasp9M28z - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JTCR-016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MesoCancerVac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MesoCART - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegargiminase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
porfimer sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7787 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TargomiRs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TroVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-5584 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Malignant Pleural Mesothelioma - Recent Pipeline Updates
Malignant Pleural Mesothelioma - Dormant Projects
Malignant Pleural Mesothelioma - Discontinued Products
Malignant Pleural Mesothelioma - Product Development Milestones
Featured News & Press Releases
May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma
Apr 23, 2015: Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation from FDA, Baron & Budd Reports
Apr 19, 2015: Early Findings with KEYTRUDA (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
Apr 19, 2015: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients
Mar 26, 2015: Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma
Mar 18, 2015: New Data Investigating Merck’s KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
Jan 20, 2015: Verastem Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma
Jan 20, 2015: Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
Dec 18, 2014: Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
Oct 24, 2014: Verastem Presents New Data on Mesothelioma Programs at the 12th International Mesothelioma Interest Group Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2015
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Biogen, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2015
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Concordia Healthcare Corp., H1 2015
Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2015
Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H1 2015
Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline plc, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by MedImmune, LLC, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica plc, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2015
Malignant Pleural Mesothelioma - Dormant Projects, H1 2015
Malignant Pleural Mesothelioma - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2015
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Aduro BioTech, Inc.
Advantagene, Inc.
Amphera BV
Bayer AG
Biogen, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CanBas Co., Ltd.
Concordia Healthcare Corp.
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline plc
Juno Therapeutics Inc.
MedImmune, LLC
Merck & Co., Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Oxford BioMedica plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Verastem, Inc.
Virttu Biologics Limited
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll